ReviewWorld journal of diabetes2022
Gut microbiota and diabetic kidney diseases: Pathogenesis and therapeutic perspectives.
Review in World journal of diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals.Frontiers in endocrinology · 2022Pooled it
- Causal relationships between the gut microbiota, immune cells, and diabetic kidney disease: a Mendelian randomization and mediation analysis.Renal failure · 2026Article
- Oral Butyrate Reduces Progression of Kidney Damage in an L-NAME-Induced Diabetic Kidney Disease Mouse Model.Diabetes, obesity & metabolism · 2026Article
- Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.Acta pharmacologica Sinica · 2026Review
- Bridging gut microbiota and renal health: Klotho as a promising therapeutic agent in DKD.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Wenyang Huazhuo formula extract ameliorates diabetic kidney disease in db/db mice and is associated with modulation of MHC class II molecules and gut microbiota.Frontiers in pharmacology · 2026Article
- Network Pharmacology Combined With Gut Microbiome and Serum Metabolomics Reveals the Therapeutic Mechanisms of Hydroxysafflor Yellow A in Diabetic Kidney Disease.Journal of diabetes research · 2026Article
- Causal effects of gut microbiota on diabetic kidney disease: insights from 16S rRNA sequencing and bidirectional Mendelian randomization.Renal failure · 2025Article
- Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies.Renal failure · 2025Review
- Metagenomic profiling of gut microbime: associating their role with the advancement of diabetic nephropathy.Antonie van Leeuwenhoek · 2025Review
- Predicting diabetic kidney disease with serum metabolomics and gut microbiota.Scientific reports · 2025Article
- Associations Between Gut Microbiota and Diabetic Nephropathy: A Mendelian Randomization Study.Aging medicine (Milton (N.S.W)) · 2025Article
- Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients.Frontiers in endocrinology · 2025Article
- A review of advances in the treatment of diabetic nephropathy by modulating intestinal flora with natural products of traditional Chinese medicine.Frontiers in pharmacology · 2025Review
- Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.Pharmaceutical biology · 2024Review
- Exploring the causal connection: insights into diabetic nephropathy and gut microbiota from whole-genome sequencing databases.Renal failure · 2024Article
- Molecular Therapeutics for Diabetic Kidney Disease: An Update.International journal of molecular sciences · 2024Review
- Association of dietary live microbe intake with diabetic kidney disease in patients with type 2 diabetes mellitus in US adults: a cross-sectional study of NHANES 1999-2018.Acta diabetologica · 2024Article
- Integrated 16S rRNA sequencing and metabolomic analysis reveals the potential protective mechanism of Germacrone on diabetic nephropathy in mice.Acta biochimica et biophysica Sinica · 2024Article
- Dietary fiber intake and its association with diabetic kidney disease in American adults with diabetes: A cross-sectional study.World journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is one of the major chronic complications of diabetes mellitus (DM), as well as a main cause of end-stage renal disease. Over the last few years, substantial research studies have revealed a contributory role of gut microbiota in the process of DM and DKD. Metabolites of gut microbiota like lipopolysaccharide, short-chain fatty acids, and trimethylamine N-oxide are key mediators of microbial-host crosstalk. However, the underlying mechanisms of how gut microbiota influences the onset and progression of DKD are relatively unknown. Besides, strategies to remodel the composition of gut microbiota or to reduce the metabolites of microbiota have been found recently, representing a new potential remedial target for DKD. In this mini-review, we will address the possible contribution of the gut microbiota in the pathogenesis of DKD and its role as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.